Novel role of microRNA‑126 in digestive system cancers: From bench to bedside (Review)
- Authors:
- Mingli Hu
- Shengwei Xiong
- Qiaofeng Chen
- Shixuan Zhu
- Xiaodong Zhou
-
Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China - Published online on: October 29, 2018 https://doi.org/10.3892/ol.2018.9639
- Pages: 31-41
-
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, et al: MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA. 103:9136–9141. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Moretti F, Thermann R and Hentze MW: Mechanism of translational regulation by miR-2 from sites in the 5′ untranslated region or the open reading frame. RNA. 16:2493–2502. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen CZ: MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Z, Li Z, Li Y and Zang A: MicroRNA and signaling pathways in gastric cancer. Cancer Gene Ther. 21:305–316. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D: miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 15:272–284. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R and Olson EN: The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 15:261–271. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Meister J and Schmidt MHH: miR-126 and miR-126* New players in cancer. ScientificWorldJournal. 10:2090–2100. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Soncin F, Mattot V, Lionneton F, Spruyt N, Lepretre F, Begue A and Stehelin D: VE-statin, an endothelial repressor of smooth muscle cell migration. EMBO J. 22:5700–5711. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Parker LH, Schmidt M, Jin SW, Gray AM, Beis D, Pham T, Frantz G, Palmieri S, Hillan K, Stainier DY, et al: The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature. 428:754–758. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Campagnolo L, Leahy A, Chitnis S, Koschnick S, Fitch MJ, Fallon JT, Loskutoff D, Taubman MB and Stuhlmann H: EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. Am J Pathol. 167:275–284. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Morgenbesser SD, Dufault MR, Martin TB, Lim E, Callahan M, Weber W, Winter SF, McLaren RP, Richards B, Cook BP, et al: Characterization of EGFL7 expression and function in tumorigenesis and angiogenesis. Cancer Res. 65 Suppl 9:S11032005. | |
|
Hu MH, Ma CY, Wang XM, Ye CD, Zhang GX, Chen L and Wang JG: MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression. Oncotarget. 7:66922–66934. 2016.PubMed/NCBI | |
|
Harris TA, Yamakuchi M, Ferlito M, Mendell JT and Lowenstein CJ: MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA. 105:1516–1521. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tang ST, Wang F, Shao M, Wang Y and Zhu HQ: MicroRNA-126 suppresses inflammation in endothelial cells under hyperglycemic condition by targeting HMGB1. Vascul Pharmacol. 88:48–55. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Feng R, Chen X, Yu Y, Su L, Yu B, Li J, Cai Q, Yan M, Liu B and Zhu Z: miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 298:50–63. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ebrahimi F, Gopalan V, Smith RA and Lam AK: miR-126 in human cancers: Clinical roles and current perspectives. Exp Mol Pathol. 96:98–107. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, et al: A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 129:1401–1414. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W and Tuschl T: Identification of tissue-specific microRNAs from mouse. Curr Biol. 12:735–739. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, Swisher SG, Wu TT, Ajani JA and Xu XC: Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 128:132–143. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ, Wang TY, Li HC and Wu XN: Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett. 5:1639–1642. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu R, Gu J, Jiang P, Zheng Y, Liu X, Jiang X, Huang E, Xiong S, Xu F, Liu G, et al: DNMT1-microRNA126 epigenetic circuit contributes to esophageal squamous cell carcinoma growth via ADAM9-EGFR-AKT signaling. Clin Cancer Res. 21:854–863. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Meng F, Ma J, Yu Y, Hua X, Qin J and Li Y: Insulin receptor substrate-1 and Golgi phosphoprotein 3 are downstream targets of miR-126 in esophageal squamous cell carcinoma. Oncol Rep. 32:1225–1233. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nie ZC, Weng WH, Li J, Xu YT and Li Z: Down-regulation of miR-126 in esophageal carcinoma tissues and its inhibition effect on proliferation and migration of esophageal carcinoma cell line EC109. Tumor. 35:55–64. 2015. | |
|
Nie ZC, Weng WH, Shang YS, Long Y, Li J, Xu YT and Li Z: MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway. Int J Clin Exp Pathol. 8:4745–4754. 2015.PubMed/NCBI | |
|
Kong R, Ma Y, Feng J, Li S, Zhang W, Jiang J, Zhang J, Qiao Z, Yang X and Zhou B: The crucial role of miR-126 on suppressing progression of esophageal cancer by targeting VEGF-A. Cell Mol Biol Lett. 21:32016. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Wang F and Qi Y: miR-126 inhibits the invasion of gastric cancer cell in part by targeting Crk. Eur Rev Med Pharmacol Sci. 18:2031–2037. 2014.PubMed/NCBI | |
|
Yue S, Shi H, Han J, Zhang T, Zhu W and Zhang D: Prognostic value of microRNA-126 and CRK expression in gastric cancer. Onco Targets Ther. 9:6127–6135. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Otsubo T, Akiyama Y, Hashimoto Y, Shimada S, Goto K and Yuasa Y: MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS One. 6:e166172011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Chen X, Li P, Su L, Yu B, Cai Q, Li J, Yu Y, Liu B and Zhu Z: CRKL promotes cell proliferation in gastric cancer and is negatively regulated by miR-126. Chem Biol Interact. 206:230–238. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen H, Li L, Wang S, Lei Y, Ge Q, Lv N, Zhou X and Chen C: Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A. Oncotarget. 5:11873–11885. 2014.PubMed/NCBI | |
|
Liu LY, Wang W, Zhao LY, Guo B, Yang J, Zhao XG, Hou N, Ni L, Wang AY, Song TS, et al: Mir-126 inhibits growth of SGC-7901 cells by synergistically targeting the oncogenes PI3KR2 and Crk, and the tumor suppressor PLK2. Int J Oncol. 45:1257–1265. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Chen X, Su L, Li P, Cai Q, Liu B, Wu W and Zhu Z: MicroRNA-126 inhibits cell proliferation in gastric cancer by targeting LAT-1. Biomed Pharmacother. 72:66–73. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Z, Wang R, Zhang T and Dong X: MicroRNA-126 regulates migration and invasion of gastric cancer by targeting CADM1. Int J Clin Exp Pathol. 8:8869–8880. 2015.PubMed/NCBI | |
|
Wang P, Li Z, Liu H, Zhou D, Fu A and Zhang E: MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2. Biochem Biophys Res Commun. 479:91–96. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Zhou Y, Fei X, Chen X, Yan J, Liu B and Zhu Z: ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126. Oncol Rep. 37:2033–2040. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Zhou Y, Fei X, Chen X and Zhu Z: Regulator of G-protein signaling 3 targeted by miR-126 correlates with poor prognosis in gastric cancer patients. Anticancer Drugs. 28:161–169. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Banerjee N, Kim H, Talcott S and Mertens-Talcott S: Pomegranate polyphenolics suppressed azoxymethane-induced colorectal aberrant crypt foci and inflammation: Possible role of miR-126/VCAM-1 and miR-126/PI3K/AKT/mTOR. Carcinogenesis. 34:2814–2822. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Guo C, Sah JF, Beard L, Willson JK, Markowitz SD and Guda K: The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer. 47:939–946. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hansen TF, Andersen CL, Nielsen BS, Spindler KL, Sørensen FB, Lindebjerg J, Brandslund I and Jakobsen A: Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer. Oncol Lett. 2:1101–1106. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Wang X, Xu B, Wang B, Wang Z, Liang Y, Zhou J, Hu J and Jiang B: Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep. 30:1976–1984. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan W, Guo YQ, Li XY, Deng MZ, Shen ZH, Bo CB, Dai YF, Huang MY, Yang ZY, Quan YS, et al: MicroRNA-126 inhibits colon cancer cell proliferation and invasion by targeting the chemokine (C-X-C motif) receptor 4 and Ras homolog gene family, member A, signaling pathway. Oncotarget. 7:60230–60244. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Zhou Y, Feng X, An P, Quan X, Wang H, Ye S, Yu C, He Y and Luo H: MicroRNA-126 functions as a tumor suppressor in colorectal cancer cells by targeting CXCR4 via the AKT and ERK1/2 signaling pathways. Int J Oncol. 44:203–210. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li N, Tang A, Huang S, Li Z, Li X, Shen S, Ma J and Wang X: miR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway. Mol Cell Biochem. 380:107–119. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Feng X, Liu YL, Ye SC, Wang H, Tan WK, Tian T, Qiu YM and Luo HS: Down-regulation of miR-126 is associated with colorectal cancer cells proliferation, migration and invasion by targeting IRS-1 via the AKT and ERK1/2 signaling pathways. PLoS One. 8:e812032013. View Article : Google Scholar : PubMed/NCBI | |
|
Li N, Li X, Huang S, Shen S and Wang X: miR-126 inhibits colon cancer proliferation and invasion through targeting IRS1, SLC7A5 and TOM1 gene. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 38:809–817. 2013.(In Chinese). PubMed/NCBI | |
|
Du C, Lv Z, Cao L, Ding C, Gyabaah OA, Xie H, Zhou L, Wu J and Zheng S: miR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2. J Transl Med. 12:2592014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao C, Li Y, Zhang M, Yang Y and Chang L: miR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting Sox2. Hum Cell. 28:91–99. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ji JS, Xu M, Song JJ, Zhao ZW, Chen MJ, Chen WQ, Tu JF and Yang XM: Inhibition of microRNA-126 promotes the expression of Spred1 to inhibit angiogenesis in hepatocellular carcinoma after transcatheter arterial chemoembolization: In vivo study. Onco Targets Ther. 9:4357–4367. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gong C, Fang J, Li G, Liu HH and Liu ZS: Effects of microRNA-126 on cell proliferation, apoptosis and tumor angiogenesis via the down-regulating ERK signaling pathway by targeting EGFL7 in hepatocellular carcinoma. Oncotarget. 8:52527–52542. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xiang LY, Ou HH, Liu XC, Chen ZJ, Li XH, Huang Y and Yang DH: Loss of tumor suppressor miR-126 contributes to the development of hepatitis B virus-related hepatocellular carcinoma metastasis through the upregulation of ADAM9. Tumor Biol. 39:10104283177091282017. View Article : Google Scholar | |
|
Hamada S, Satoh K, Fujibuchi W, Hirota M, Kanno A, Unno J, Masamune A, Kikuta K, Kume K and Shimosegawa T: miR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res. 10:3–10. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jiao LR, Frampton AE, Jacob J, Pellegrino L, Krell J, Giamas G, Tsim N, Vlavianos P, Cohen P, Ahmad R, et al: MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One. 7:e320682012. View Article : Google Scholar : PubMed/NCBI | |
|
Feng SD, Mao Z, Liu C, Nie YS, Sun B, Guo M and Su C: Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma. Onco Targets Ther. 10:5591–5604. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pagano F, De Marinis E, Grignani F and Nervi C: Epigenetic role of miRNAs in normal and leukemic hematopoiesis. Epigenomics. 5:539–552. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yan J, Dang Y, Liu S, Zhang Y and Zhang G: LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumor Biol. 37:16345–16355. 2016. View Article : Google Scholar | |
|
Wang XY, Wu MH, Liu F, Li Y, Li N, Li GY and Shen SR: Differential miRNA expression and their target genes between NGX6-positive and negative colon cancer cells. Mol Cell Biochem. 345:283–290. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang JH, Chen XT, Wen ZS, Zheng M, Deng JM, Wang MZ, Lin HX, Chen K, Li J, Yun JP, et al: High expression of GOLPH3 in esophageal squamous cell carcinoma correlates with poor prognosis. PLoS One. 7:e456222012. View Article : Google Scholar : PubMed/NCBI | |
|
Shi CS, Huang NN and Kehrl JH: Regulator of G-protein signaling 3 isoform 1 (PDZ-RGS3) enhances canonical Wnt signaling and promotes epithelial mesenchymal transition. J Biol Chem. 287:33480–33487. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Singh SK, Chen NM, Hessmann E, Siveke J, Lahmann M, Singh G, Voelker N, Vogt S, Esposito I, Schmidt A, et al: Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. EMBO J. 34:517–530. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Wang S and Huang C: VEGFA+936C/T and −634G/C polymorphisms and gastric cancer risk: A meta-analysis. Asian Pac J Cancer Prev. 12:1979–1983. 2011.PubMed/NCBI | |
|
Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA, Nuovo G, Marsh CB and Nana-Sinkam SP: MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 373:607–612. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Xiong Y, Kotian S, Zeiger MA, Zhang L and Kebebew E: miR-126-3p inhibits thyroid cancer cell growth and metastasis, and is associated with aggressive thyroid cancer. PLoS One. 10:e01304962015. View Article : Google Scholar : PubMed/NCBI | |
|
Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T and Baserga R: Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem. 282:32582–32590. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hara T, Jones MF, Subramanian M, Li XL, Ou O, Zhu Y, Yang Y, Wakefield LM, Hussain SP, Gaedcke J, et al: Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells. Oncotarget. 5:7635–7650. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Otsubo T, Akiyama Y, Yanagihara K and Yuasa Y: SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer. 98:824–831. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis. 9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Okumura E, Fukuhara T, Yoshida H, Hanada Si S, Kozutsumi R, Mori M, Tachibana K and Kishimoto T: Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/M-phase transition. Nat Cell Biol. 4:111–116. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Xu WH, Zhang JB, Dang Z, Li X, Zhou T, Liu J, Wang DS, Song WJ and Dou KF: Long non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma. Int J Biol Sci. 10:664–676. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang SC, Lin JK, Wang HS, Yang SH, Li AF and Chang SC: Nuclear expression of CXCR4 is associated with advanced colorectal cancer. Int J Colorectal Dis. 25:1185–1191. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Li N, Wu M, Li X, Luo Z and Wang X: Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4. Mol Cell Biochem. 381:233–242. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wolfe A, Thomas A, Edwards G, Jaseja R, Guo GL and Apte U: Increased activation of the Wnt/β-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther. 338:12–21. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Huang J, Xiao D, Li G, Ma J, Chen P, Yuan W, Hou F, Ge J, Zhong M, Tang Y, et al: EphA2 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells. Oncogene. 33:2737–2747. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yanaka Y, Muramatsu T, Uetake H, Kozaki K and Inazawa J: miR-544a induces epithelial-mesenchymal transition through the activation of WNT signaling pathway in gastric cancer. Carcinogenesis. 36:1363–1371. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Germano G, Allavena P and Mantovani A: Cytokines as a key component of cancer-related inflammation. Cytokine. 43:374–379. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ma J, Liu J, Wang Z, Gu X, Fan Y, Zhang W, Xu L, Zhang J and Cai D: NF-kappaB-dependent microRNA-425 upregulation promotes gastric cancer cell growth by targeting PTEN upon IL-1β induction. Mol Cancer. 13:402014. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Z, Meng C, Wang S, Zhou N, Guan M, Bai C, Lu S, Han Q and Zhao RC: MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma. BMC Cancer. 14:6162014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang JL, Hu Y, Kong X, Wang ZH, Chen HY, Xu J and Fang JY: Candidate microRNA biomarkers in human gastric cancer: A systematic review and validation study. PLoS One. 8:e736832013. View Article : Google Scholar : PubMed/NCBI | |
|
Barshack I, Meiri E, Rosenwald S, Lebanony D, Bronfeld M, Aviel-Ronen S, Rosenblatt K, Polak-Charcon S, Leizerman I, Ezagouri M, et al: Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression. Int J Biochem Cell Biol. 42:1355–1362. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fidler IJ: The pathogenesis of cancer metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 3:453–458. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hansen TF, Sørensen FB, Lindebjerg J and Jakobsen A: The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. BMC Cancer. 12:832012. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Zhang Y, Zhang Y, Ding J, Wu K and Fan D: Survival prediction of gastric cancer by a seven-microRNA signature. Gut. 59:579–585. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, et al: Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 47:897–907. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Feng R, Sah BK, Beeharry MK, Yuan F, Su L, Jin X, Yan M, Liu B, Li C and Zhu Z: Dysregulation of miR-126/Crk protein axis predicts poor prognosis in gastric cancer patients. Cancer Biomark. 21:335–343. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yin J, Bai Z, Song J, Yang Y, Wang J, Han W, Zhang J, Meng H, Ma X, Yang Y, et al: Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer. Chin J Cancer Res. 26:95–103. 2014.PubMed/NCBI | |
|
Li H, Zhang H, Lu G, Li Q, Gu J, Song Y, Gao S and Ding Y: Mechanism analysis of colorectal cancer according to the microRNA expression profile. Oncol Lett. 12:2329–2336. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Imamura T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Ohashi T, Kiuchi J, Nishibeppu K, Konishi H, Shiozaki A, et al: Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer. Sci Rep. 7:57082017. View Article : Google Scholar : PubMed/NCBI | |
|
Ghosh A, Ghosh A, Datta S, Dasgupta D, Das S, Ray S, Gupta S, Datta S, Chowdhury A, Chatterjee R, et al: Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma. Int J Cancer. 138:2732–2744. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou W, Yang W, Ma J, Zhang H, Li Z, Zhang L, Liu J, Han Z, Wang H and Hong L: Role of miR-483 in digestive tract cancers: From basic research to clinical value. J Cancer. 9:407–414. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wu XM, Shao XQ, Meng XX, Zhang XN, Zhu L, Liu SX, Lin J and Xiao HS: Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin. 32:259–269. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Borel F, Konstantinova P and Jansen PL: Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol. 56:1371–1383. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liang G, Zhu Y, Jing A, Wang J, Hu F, Feng W, Xiao Z and Chen B: Cationic microRNA-delivering nanocarriers for efficient treatment of colon carcinoma in xenograft model. Gene Ther. 23:829–838. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Wang Z and Gemeinhart RA: Progress in microRNA delivery. J Control Release. 172:962–974. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li XM, Wang AM, Zhang J and Yi H: Down-regulation of miR-126 expression in colorectal cancer and its clinical significance. Med Oncol. 28:1054–1057. 2011. View Article : Google Scholar : PubMed/NCBI |
